Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease.

ABSTRACT: In sickle cell disease, respiratory infection and asthma may lead to respiratory complications that are a leading cause of morbidity and mortality. Vitamin D has anti-infective and immunomodulatory effects that may decrease the risk for respiratory infections, asthma, and acute chest syndrome. We conducted a randomized double-blind active-controlled clinical trial to determine whether monthly oral vitamin D₃ can reduce the rate of respiratory events in children with sickle cell disease. Seventy sickle cell subjects, ages 3-20 years, with baseline records of respiratory events over 1 year before randomization, underwent screening. Sixty-two subjects with 25-hydroxyvitamin D levels of 5-60 ng/mL were randomly assigned to oral vitamin D₃ (100 000 IU or 12 000 IU, n = 31

SUBMITTER: Lee MT 

PROVIDER: S-EPMC5941998 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature